Optimapharm is featured in STAT News.

Optimapharm is a mid-sized, global Contract Research Organisation turning science into hope through agile, patient-focused clinical development. We specialise in Phase I–IV clinical development, delivering Full-Service and Functional Service Provision (FSP) solutions that help sponsors move faster and execute with confidence. Beyond approval, we support continued clinical development and real-world evidence generation to optimise product lifecycles, including repositioning and promotion of approved therapies. With 2x the patient reach of the average mid-sized CRO and operations in 40+ countries, we enable accelerated regulatory pathways and rapid access to diverse patient populations, helping sponsors shorten study start-up timelines and bring forward first-patient-in.

Founded 2005